What to understand before paying for a compounded GLP-1 program: what compounded means, what the FDA does and doesn’t review, the risks tied to the medication itself, and the marketing claims that should make you slow down. Consumer information, not medical advice.
Compounded semaglutide and tirzepatide are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing, and they are not the same products as Wegovy, Ozempic, Zepbound, or Mounjaro. Primary source: FDA — Human Drug Compounding.
• No premarket review. Quality depends entirely on the specific compounding pharmacy — which is why naming and verifying that pharmacy matters (see the transparency comparison).
• Real clinical risks. The molecule carries a boxed thyroid-tumor warning and common GI side effects, worst during dose increases.
• Misleading claims. “Generic,” “same as branded,” and “FDA-approved pharmacy” are red flags, not reassurances.